Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013


5,304  Interest receivable327363  Amounts receivable714449  Prepaid and other current assets3,7551,210  Property, equipment and other assets1,523689Total assets$
82,016$
8,015Liabilities and stockholders' equity:  Accounts payable and accrued liabilities$
7,050$
3,217  Deferred collaboration revenue-18,271  Current portion of long-term obligations1,0841,417  Warrant liability3,4227,881  Long term liabilities4,2536,339  Stockholders' equity66,20730,890Total liabilities and stockholders' equity$
82,016$
8,015 

Conference Call Details OncoGenex will host a conference call at 4:30 p.m. Eastern Time today, Thursday, March 7, 2013, to provide a business update and discuss the fourth quarter and year end 2012 results.

A live event will be available on the Investor Relations section of the OncoGenex Web site at www.OncoGenex.com. Alternatively, you may access the live conference call by dialing 877-606-1416 (U.S. & Canada) or 707-287-9313 (International). A replay of the webcast will be available approximately two hours after the call and will be archived for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresecta
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BioCorRx, Inc. ( BICX ) ... a healthcare solutions organization, which focuses solely on addiction treatment; ... the U.S. alone. The Company created a unique treatment program ... compounded form for outpatient surgical implantation. The Company has exclusive ... New Zealand ) to the specially formulated Naltrexone implant. ...
(Date:3/27/2015)... , March 27, 2015 Levi & Korsinsky ... Inc. (NASDAQ: OHRP ) concerning possible violations of ... by the Company in connection with its study of ... http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact Joseph E. Levi, ... or by telephone at (212) 363-7500, toll-free: (877) 363-5972. ...
(Date:3/27/2015)... 27, 2015 /CNW Telbec/ - Russell Williams , ... Companies (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the ... on the biopharmaceutical industry. However, the association is concerned ... "We commend the government,s intent to strive for a ... to promote Quebec,s economic development ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3
... 11, 2008, the Joint Advisory Committees of the ... the Drug Safety & Risk Management Advisory Committee, ... Advisory Committee - completed a review of the ... beta-agonists (LABAs). The committees concluded that the benefits ...
... JERSEY CITY, New Jersey and PHILADELPHIA, December 11, ... microRNA-based molecular diagnostics, announced today the,commercial availability of ... now commercially available through Rosetta Genomics,CLIA-certified lab in ... To order the test, physicians may contact 1-888-522-7971, ...
Cached Medicine Technology:AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 2AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 3AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R) 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 2Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 3Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 4Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests 5
(Date:3/28/2015)... (PRWEB) March 28, 2015 Centurion Service Group ... auction on Thursday, April 2 at their Las Vegas warehouse, ... NV 89081. The sale, which consists of equipment from hospitals ... promptly at 9 a.m. PDT. , Buyers will find ... surgery equipment. “We are a one-stop-shop,” said Erik Tivin, CEO ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes ... first time, key information for understanding and treating this ... posted story on the Surviving Mesothelioma website. ... the British Columbia Cancer Agency, and PhenoPath lab in ... alterations and mutations that can lead to peritoneal ...
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), a ... jobs, has announced that it will participate as ... Annual Conference to be held April 10-11, 2015 ... OH. , The OPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
Breaking Medicine News(10 mins):Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... from Sheffield University most women still believe one-night stands ... revealed that women of all ages believe that sex ... ,The women community despite achieving liberation still feels ... of desperation or drunkenness. The research which was followed ...
... prevented in cancer patients, as a new method of delivering ... side effects such as hair loss and vomiting to the ... Bath, England, involves using tiny fibres and beads soaked in ... area in the patient's body. ,These fibres ...
... the Federal Government would provide $47,000 as funding for ... money would help the community health care provider. This ... transitional period. Health services play a major and integral ... that up with financial support. Due to lack of ...
... suspected of spreading the deadly bird flu in Israel. This ... agriculture department. ,'It's one of our working hypotheses. ... of cars and even on cameras. The journalists who came ... offices across the country,' said the health official. ...
... student of psychology is planning to record the barks and growls ... canines communicate//. ,Anna Taylor, 23, of Brighton in southern England, ... and sizes to take part in the study, it was reported ... the dogs to bark and growl including banging on doors and ...
... peptide can predict the presence of pulmonary hypertension in ... appearing in the April issue of the American //Journal ... American Thoracic Society. ,Juergen Behr, M.D., of the ... medicine at Ludwig Maximillians University in Munich, Germany, and ...
Cached Medicine News:Health News:New Method Developed To Cut Down Chemotherapy Deaths 2
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile...
The Multi-Purpose Stand Magnifier is the most versatile stand magnifier. The stand has multiple configurations allowing for all situations where hands-free magnification is needed....
... The aplanatic lens is made ... lens system consisting of two ... clearly defined, distortion-free image. This ... for patients with macular degeneration ...
... Sheets are commonly used for orbital ... The thinner 0.4 mm sheet was ... greater flexibility and to provide a ... the orbit. It is ideally suited ...
Medicine Products: